Shiv Kumar Sarin, Manoj Kumar, George Lau, Zaigham Abbas et al.
Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available ...
Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai‐Sun Wong, Jian-Gao Fan et al.
Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver disease and affects nearly a quarter of the global population. The objective of this work was to present the clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on ...
Shiv Kumar Sarin, Manoj Kumar, Mohammed Eslam, Jacob George et al.
The Asia-Pacific region is home to more than half of the global population and accounted for 62·6% of global deaths due to liver diseases in 2015. 54·3% of global deaths due to cirrhosis, 72·7% of global deaths due to hepatocellular carcinoma, and more than two-thirds of the global burden of acute v...
Shiv Kumar Sarin, Ashok Choudhury, George Lau, Ming‐Hua Zheng et al.
Background and aims COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirr...
Gamal Shiha, Alaa Ibrahim, Ahmed Helmy, Shiv Kumar Sarin et al.
Hepatic fibrosis is a common pathway leading to liver cirrhosis, which is the end result of any injury to the liver. Accurate assessment of the degree of fibrosis is important clinically, especially when treatments aimed at reversing fibrosis are being evolved. Despite the fact that liver biopsy (LB...
Masao Omata, Tatsuo Kanda, Lai Wei, Ming‐Lung Yu et al.
The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the "APASL consensus statements and recommendation on management of hepatitis C" in March, 2015, in order to revise "APASL consensus statements and management algorithms for hepatitis C virus ...
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, Vincent Wai‐Sun Wong et al.
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for the Study of the Liver (APASL) has created clinical practice guidelines focused ...
Tatsuo Kanda, George Lau, Lai Wei, Mitsuhiko Moriyama et al.
In the direct-acting antiviral (DAA) era for hepatitis C virus (HCV) infection, sustained virological response (SVR) is very high, but close attention must be paid to the possible occurrence of hepatocellular carcinoma (HCC) and reactivation of hepatitis B virus (HBV) in patients with co-infection w...
Masao Omata, Tatsuo Kanda, Lai Wei, Ming‐Lung Yu et al.
The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on "APASL consensus statements and recommendations for management of hepatitis C" in March 2015 to revise the "APASL consensus statements and management algorithms for hepatitis C virus infection...
Manoj Kumar, Zaigham Abbas, Milad Azami, M. А. Belopolskaya et al.
Hepatitis B virus (HBV) infection still remains a major public health issue in the Asia-Pacific region. Most of the burden of HBV-related disease results from infections acquired in infancy through perinatal or early childhood exposure to HBV in Asia-Pacific. Hepatitis B during pregnancy presents un...
George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi et al.
In Asia-Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progr...
Geoffrey C. Farrell
This issue of the Journal features the revised Asia–Pacific Consensus Statements on hepatitis C virus (HCV) infection prevention, diagnosis, management and treatment.1 These guidelines have been developed by the region's hepatology society, the Asia–Pacific Association for the Study of the Liver (AP...
Dong‐Sik Kim, Young‐In Yoon, Beom Kyung Kim, Ashok Choudhury et al.
Liver transplantation is a highly complex and challenging field of clinical practice. Although it was originally developed in western countries, it has been further advanced in Asian countries through the use of living donor liver transplantation. This method of transplantation is the only available...
Tatsuo Kanda, George Lau, Lai Wei, Mitsuhiko Moriyama et al.
Chronic hepatitis C virus (HCV) infection is common among patients with chronic kidney disease (CKD) and those on hemodialysis due to nosocomial infections and past blood transfusions. While a majority of HCV-infected patients with end-stage renal disease are asymptomatic, some may ultimately experi...
Masao Omata, Tatsuo Kanda, Osamu Yokosuka, Dorothy H. Crawford et al.
Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4-1.0, 14.7, 0.1-0.3, 0.9-1.9, 1.0-2.0, 5, 4.4-8.6 and 0.5-1.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (...